截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 | RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 | RMB | | 346,749,997 ...

继李先生辞任后，杨丽珊女士(杨女士)已获委任为(i)联席公司秘书;及(ii)法律程序文件接收代理人;以及 (iii)授权代表，自2025年12月30日起生效。 心泰医疗(02291)发布公告，李健威先生(李先生)因其他事务已辞任本公司以下职位，自2025年12月30日 起生效：(i)联席公司秘书;(ii)根据香港联合交易所有限公司(联交所)证券上市规则第19A.13(2)条的规 定，代表本公司在香港送达法律程序文件及通知书的代理人(法律程序文件接收代理人);及(iii)《公司条 例》(香港法例第622章)第16部及《上市规则》第3.05条规定的授权代表。 ...

继李先生辞任后，杨丽珊女士(杨女士)已获委任为(i)联席公司秘书;及(ii)法律程序文件接收代理人;以及 (iii)授权代表，自2025年12月30日起生效。 智通财经APP讯，心泰医疗(02291)发布公告，李健威先生(李先生)因其他事务已辞任本公司以下职位， 自2025年12月30日起生效：(i)联席公司秘书;(ii)根据香港联合交易所有限公司(联交所)证券上市规则第 19A.13(2)条的规定，代表本公司在香港送达法律程序文件及通知书的代理人(法律程序文件接收代理 人);及(iii)《公司条例》(香港法例第622章)第16部及《上市规则》第3.05条规定的授权代表。 ...

董事会进一步宣布，继李辞任后，杨丽珊获委任为(i)联席公司秘书；及(ii)法律程序文件接收代理人； 以及(iii)授权代表，自2025年12月30日起生效。 格隆汇12月30日丨心泰医疗(02291.HK)公告，李健威因其他事务已辞任公司以下职位，自2025年12月30 日起生效：(i)联席公司秘书；(ii)根据香港联合交易所有限公司证券上市规则("《上市规则》")第 19A.13(2)条的规定，代表公司在香港送达法律程序文件及通知书的代理人；及(iii)《公司条例》(香港法 例第622章)第16部及《上市规则》第3.05条规定的授权代表。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2291） 1 (i) 聯席公司秘書（「聯席公司秘書」）； (ii) 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「《上市規則》」）第 19A.13(2)條的規定，代表本公司在香港送達法律程序文件及通知書的代理人 （「法律程序文件接收代理人」）；及 (iii) 《公司條例》（香港法例第622章）第16部及《上市規則》第3.05條規定的授權代 表（「授權代表」）。 聯席公司秘書、法律程序文件接收代理人及授權代表變更 聯席公司秘書、法律程序文件接收代理人及授權代表變更 樂普心泰醫療科技（上海）股份有限公司（「本公司」）及其附屬公司（統稱「本集 團」）的董事（「董事」）會（「董事會」）宣佈，李健威 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

Core Viewpoint - The stock price of XinTai Medical (02291) has been on a downward trend since August 26, following a significant share reduction by its major shareholder, Lepu Medical, which has led to decreased investor confidence and trading volume [1][2][4]. Group 1: Stock Performance - On November 19, XinTai Medical's stock price hit a low of HKD 17.95, marking the first time it fell below HKD 18 since a 49.26% increase on April 22 [1]. - The stock closed at HKD 17.20 on December 8, nearing its recent low of HKD 17.01 [1]. - The downward trend began after the major shareholder's announcement on August 26, which caused an immediate sell-off, leading to a 12.75% drop on that day [3]. Group 2: Shareholder Actions - On August 26, Lepu Medical announced the sale of 11.14 million shares at HKD 22.79 each, representing 3.21% of XinTai Medical's total issued shares [2]. - Despite the announcement claiming confidence in the company's operations, the immediate market reaction was negative, with significant sell-offs and a subsequent decline in trading volume [4]. Group 3: Market Dynamics - Following the announcement, trading volume dropped significantly, with daily averages falling below 1 million shares, indicating a lack of confidence among investors [4]. - The stock's performance has raised concerns about XinTai Medical's status in the Hong Kong Stock Connect, with an average market capitalization of HKD 68.85 billion, just above the HKD 60.71 billion threshold [6]. Group 4: Industry Context - A nationwide procurement initiative for structural heart disease occluders has been initiated, which could impact pricing and market dynamics for XinTai Medical's products [9][10]. - The market for heart occluders is projected to exceed HKD 60 billion by 2025, with significant growth expected [10]. - XinTai Medical's revenue from congenital heart disease occluders was HKD 161 million in the first half of the year, accounting for 48.7% of total revenue, indicating its importance to the company's financial health [11].

Core Viewpoint - The stock price of XinTai Medical (02291) has been on a downward trend since August 26, following a major shareholder's announcement of share reduction, leading to concerns about the company's market position and potential risks to its inclusion in the Hong Kong Stock Connect program [1][5]. Group 1: Stock Performance - On November 19, XinTai Medical's stock price hit a low of HKD 17.95, marking the first time it fell below HKD 18 since a significant increase of 49.26% on April 22 [1]. - The stock closed at HKD 17.20 on December 8, nearing its recent low of HKD 17.01, indicating a continued decline [1]. - The downward trend began after the major shareholder, Lepu Medical, announced the sale of 11.14 million shares at HKD 22.79 each, representing approximately 3.21% of the company's total issued shares [1][2]. Group 2: Market Reaction - Following the announcement of the share reduction, there was immediate selling pressure, with the stock price dropping nearly 9% within the first minute of trading on August 26, and closing down 12.75% for the day [2]. - The stock has since experienced a prolonged decline, characterized by a "seven consecutive days of decline" followed by an "eleven consecutive days of decline," indicating a lack of buying support [2][3]. Group 3: Trading Volume and Market Sentiment - The trading volume on the day of the announcement reached 16.16 million shares, but subsequent days saw average daily volumes drop below 1 million shares, reflecting a lack of confidence among investors [3]. - The low trading volume and continuous decline suggest that investors are hesitant about the stock's value growth, leading to a cautious market sentiment [3]. Group 4: Potential Risks to Market Position - XinTai Medical's average market capitalization during the review period is HKD 6.885 billion, only slightly above the HKD 6.071 billion threshold for inclusion in the Hong Kong Stock Connect program [5]. - The next review for the Hong Kong Stock Connect is scheduled for March 2025, with results announced on February 25, 2025, creating a critical timeframe for the company to stabilize its market position [5]. Group 5: Industry Developments - Recent announcements regarding the nationwide centralized procurement of structural heart disease occluders could significantly impact XinTai Medical's market dynamics, as this initiative aims to lower prices and increase competition [10][11]. - The market for heart occluders is projected to exceed HKD 6 billion by 2025, with a double-digit growth rate, indicating a robust demand for these medical devices [10]. - XinTai Medical's revenue from congenital heart disease occluders was HKD 161 million in the first half of the year, accounting for 48.7% of total revenue, highlighting its importance as a core revenue source [11].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 因本公司是於中華人民共和國註冊成立，「法定股本」之概念不適用於本公司。於I節中所示的資料是指本公司的「註冊股本」。 ...